Kaneka officially starts continuous manufacturing under GMP

Food and Healthcare Press Releases Tuesday August 14, 2018 15:18
TOKYO--14 Aug--PRNewswire/InfoQuest
Commercial production utilizing flow chemistry began June 2018 at Kaneka Singapore

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Mamoru Kadokura) have installed continuous manufacturing equipment to be applied to pharmaceutical products at Kaneka Singapore Co. (Pte.) Ltd, (Headquarters: Singapore; President: Kazuhiko Yamada) with commercial production under cGMP already underway as of June 2018.

In the field of small molecule pharmaceutical products, the recent demands have begun to   trend toward an increased number of more diversified and smaller volume targets. With these changes, more efficient production technology is needed to address the broad range of targets now required. Continuous manufacturing, or Flow Chemistry, is a manufacturing technology that allows the introduction   of raw materials with little to no operator exposure and presents an   easy, safe and convenient approach to manufacturing, including reactions that may require tough or dangerous conditions under typical batch reaction conditions. Our equipment is a unique, Kaneka designed reactor that allows diversity of application through the ability to select the relevant parameters of the reaction tubing based on laboratory and scale-up research providing the highest performance of reactions. Kaneka Singapore has been qualified as a manufacturer from the US FDA *1 in 2017, and we expect to apply this   continuous manufacturing infrastructure to various Regulatory Starting Material (RSM), Intermediate, and API projects, including targets requiring GMP *2 production.

Kaneka has capability from process development to commercial production with excellent quality assurance, and we now aim to expand our solution services in the Health Care business field utilizing this new technology.

*1 Abbreviated name of Food and Drug Administration. It is an agency within the Department of Health and Human Services in US and   has responsibility for regulating the manufacturing, marketing, and distribution of pharmaceutical products.

*2 Abbreviated name of Good Manufacturing Practice, the recommended guidelines and minimum requirements to ensure that products are consistently high in quality.
< Kaneka Singapore Co. (Pte.) Ltd. >
Representative: CEO, Kazuhiko Yamada
Paid-in Capital: 16 million Singapore dollars
Headquarter: Singapore
Establishment: 1979
Business field: Sales and manufacturing of pharmaceutical products.
Contact:
Alan Walker
VP Pharma, Kaneka Americas Holding
(212) 705-4392
Photo - https://mma.prnewswire.com/media/729329/Kaneka_Press_Release_Image.jpg
Logo - https://mma.prnewswire.com/media/635217/Kaneka_Corporation_Logo.jpg

Latest Press Release

Brain Health Supplements Market Expecting an Outstanding Growth Till 2025

The global brain health supplements market size is expected to reach USD 10.7 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 8.2% over the forecast period. Growing health concerns over depression, anxiety,...

Menarini Silicon Biosystems Launches VRNxT Volume Reduction Instrument

Menarini Silicon Biosystems, the pioneer of liquid biopsy and rare cell technologies, announced that it will launch the new VRNxT(TM), a volume reduction instrument optimized to remove manual sample volume reduction steps in cellular biology...

BREASTFEEDING CAMPAIGN SETS A NEW REGIONAL STANDARD FOR SUSTAINABLE COMMUNICATION

The "6 months mother's milk is all you need" campaign has been awarded South East Asia PR Campaign of the year and Cause related public awareness campaign of the Year by Campaign Asia at the PR awards in Hong Kong last month. Initiated by Save The...

Daewoong Pharmaceutical participated in the IMCAS Asia 2019 to introduce the excellence of NABOTA

Daewoong Pharmaceutical Co., Ltd, a world-leading botulinum toxin manufacturer in Korea, announced its participation in IMCAS Asia 2019 held in Bali, Indonesia July 5-7, 2019 to introduce the excellence of NABOTA(R) (Prabotulinumtoxin A). The 13th year...

ISTH Announces Launch Of New Global Education Initiative In Gene Therapy For Hemophilia

The International Society on Thrombosis and Haemostasis (ISTH) is pleased to announce the official launch of Gene Therapy in Hemophilia: An ISTH Education Initiative. This landmark launch, the first of its kind in hemophilia, will take place during the...

Related Topics